AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win

AbbVie will submit the LUNA data to global regulators in menstrual migraine – an indication with no specifically approved therapies. There are currently no targeted therapies specifically approved for menstrual migraine, though other anti-migraine drugs are used off-label in this indication. AbbVie will submit these data to global health authorities. Credit: PeopleImages / Shutterstock.com. AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for a label expansion into a new indication. During the Phase III LUNA study (NCT06806293), which enrolled 468 adults with either pure menstrual migraine or menstrual-related migraine…

Source: Clinical Trials Arena